-
February 14, 2013
Peregrine Pharmaceuticals (PPHM) recently announced phase II data on its oncology candidate, bavituximab. The ...
-
February 14, 2013
Alexion Pharmaceuticals Inc.'s (ALXN) fourth quarter 2012 earnings (excluding special items but including ...
-
February 13, 2013
Amgen (AMGN) recently provided an update on its long-term strategy. The company said that it intends to focus on the ...
-
February 13, 2013
Seattle Genetics, Inc. (SGEN) reported fourth quarter 2012 net loss per share of 9 cents, narrower than the Zacks ...
-
February 13, 2013
Theravance Inc.'s (THRX) fourth quarter 2012 loss of 33 cents per share was narrower than the Zacks Consensus loss ...
-
February 12, 2013
UCB (UCBJF) and Amgen Inc. (AMGN) recently announced their decision to discontinue a phase III program being ...
-
February 12, 2013
Recently, Celgene Corporation (CELG) announced that the US Food and Drug Administration (FDA) will review the ...
-
February 12, 2013
MannKind Corporation's (MNKD) loss of 23 cents per share in the fourth quarter of 2012 was wider than the Zacks ...
-
February 11, 2013
Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM ...
-
February 11, 2013
Lannett Company, Inc. (LCI) reported second quarter fiscal 2013 earnings of 10 cents per share, above the Zacks ...
-
February 11, 2013
The US Food and Drug Administration (FDA) recently delivered encouraging news to Celgene Corporation (CELG) by ...
-
February 08, 2013
Alnylam Pharmaceuticals Inc.'s (ALNY) fourth quarter 2012 loss of $1.20 per share was narrower than the Zacks ...
-
February 07, 2013
Medivation, Inc. (MDVN) recently announced that its partner Astellas Pharma Inc. (ALPMY) reported Xtandi ...
-
February 07, 2013
Vivus Inc. (VVUS) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. ...
-
February 06, 2013
Vertex Pharmaceuticals Inc. (VRTX) recently announced that the Health Service Executive (HSE) in the Republic of ...
-
February 06, 2013
Good news flowed in at UCB (UCBJF) from Europe when the European Union (EU) approved Vimpat (lacosamide) as a single ...
-
February 05, 2013
Alnylam Pharmaceuticals Inc. (ALNY) recently entered into an exclusive global alliance with The Medicines Company ...
-
February 05, 2013
Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option ...
-
February 04, 2013
Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris ...
-
February 01, 2013
Alkermes plc (ALKS) reported earnings of 14 cents per share in the third quarter of fiscal 2013 (ended December 31, ...
